Biotech

SPDR(R) S&P(R) Biotech ETF

$99.13

Compare similar ETFs

Fund Size
Dividend
Fees
Current
(R) S&P(R) Biotech ETF XBI
Fund Size
$8.29 Billion
Dividend
0.1%
Fees
0.35%
Biotechnology ETF IBB
Fund Size
$8.46 Billion
Dividend
0.3%
Fees
0.44%
ARK Genomic Revolution ETF ARKG
Fund Size
$1.47 Billion
Dividend
-
Fees
0.75%
NYSE Arca Biotechnology Index Fund FBT
Fund Size
$1.21 Billion
Dividend
-
Fees
-
Biotechnology & Genome ETF PBE
Fund Size
$324 Million
Dividend
0.0%
Fees
-
View 7 similar ETFs →

Average metrics of all companies in portfolio

Compare to
Market
Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares. $27.7 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price. 0.26 %
Beta Indicates the relationship between the price performance of a share and the market. 0.9315
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth. 146.84
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything -42.43
Profitable Companies 34
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued. 72.24
Price to Sales Ratio Market cap divided by the revenue in the most recent year. 15.34
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company 6.51
Compare to
Market
Enterprise Value to EBIT Enterprise Value divided by EBIT -142.23
Enterprise Value to Revenue Enterprise value divided by revenue 563.01
Total Debt to Enterprise Value Total debt divided by enterprise value -0.12
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary. NaN
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability. -6948.76%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago. -
Return on Equity Equity divided by market cap. 9.75%
Return on Assets Indicates a company's profitability in relation to its total assets. -16.27%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits. -21.41%

Industries

Healthcare 86.4%
Other 3.4%
Consumer Staples 0.7%
Industrials 0.7%
N/A 8.8%

Market cap

Micro Cap 1%
Small Cap 14%
Mid Cap 41%
Large Cap 41%
Mega Cap 3%

147 Investments

P/E-Ratio
Total Investment
Weight
State Street Global Advisors logo

State Street Global Advisors

P/E-Ratio
n/a
Total Investment
$594 Million
Weight
7.7%
United Therapeutics Corp logo

UTHR - Manufacturing

United Therapeutics Corp

P/E-Ratio
14.8
Total Investment
$206 Million
Weight
2.7%
Incyte Corp logo

INCY - Professional, Scientific, and Technical Services

Incyte Corp

P/E-Ratio
450.2
Total Investment
$202 Million
Weight
2.6%
Exact Sciences Corp logo

EXAS - Professional, Scientific, and Technical Services

Exact Sciences Corp

P/E-Ratio
-53.9
Total Investment
$202 Million
Weight
2.6%
Alnylam Pharmaceuticals Inc logo

ALNY - Manufacturing

Alnylam Pharmaceuticals Inc

P/E-Ratio
-99.2
Total Investment
$202 Million
Weight
2.6%
AbbVie Inc logo

ABBV - Manufacturing

AbbVie Inc

P/E-Ratio
60.9
Total Investment
$198 Million
Weight
2.6%
Gilead Sciences Inc logo

GILD - Manufacturing

Gilead Sciences Inc

P/E-Ratio
911.8
Total Investment
$197 Million
Weight
2.6%
Natera Inc logo

NTRA - Health Care and Social Assistance

Natera Inc

P/E-Ratio
-99.0
Total Investment
$195 Million
Weight
2.5%
Sarepta Therapeutics Inc logo

SRPT - Manufacturing

Sarepta Therapeutics Inc

P/E-Ratio
100.3
Total Investment
$195 Million
Weight
2.5%
Biogen Inc logo

BIIB - Manufacturing

Biogen Inc

P/E-Ratio
14.2
Total Investment
$193 Million
Weight
2.5%
Moderna Inc logo

MRNA - Manufacturing

Moderna Inc

P/E-Ratio
-7.7
Total Investment
$190 Million
Weight
2.5%
Insmed Inc logo

INSM - Manufacturing

Insmed Inc

P/E-Ratio
-15.2
Total Investment
$190 Million
Weight
2.5%
Amgen Inc logo

AMGN - Manufacturing

Amgen Inc

P/E-Ratio
34.6
Total Investment
$189 Million
Weight
2.5%
Vertex Pharmaceuticals Inc logo

VRTX - Manufacturing

Vertex Pharmaceuticals Inc

P/E-Ratio
-248.5
Total Investment
$186 Million
Weight
2.4%
Viking Therapeutics Inc logo

VKTX - Manufacturing

Viking Therapeutics Inc

P/E-Ratio
-56.8
Total Investment
$185 Million
Weight
2.4%
Neurocrine Biosciences Inc logo

NBIX - Manufacturing

Neurocrine Biosciences Inc

P/E-Ratio
33.6
Total Investment
$183 Million
Weight
2.4%
Regeneron Pharmaceuticals Inc logo

REGN - Manufacturing

Regeneron Pharmaceuticals Inc

P/E-Ratio
18.1
Total Investment
$177 Million
Weight
2.3%
BioMarin Pharmaceutical Inc logo

BMRN - Manufacturing

BioMarin Pharmaceutical Inc

P/E-Ratio
39.4
Total Investment
$161 Million
Weight
2.1%
Cytokinetics Inc logo

CYTK - Manufacturing

Cytokinetics Inc

P/E-Ratio
-10.4
Total Investment
$130 Million
Weight
1.7%
Blueprint Medicines Corp logo

BPMC - Manufacturing

Blueprint Medicines Corp

P/E-Ratio
-47.5
Total Investment
$124 Million
Weight
1.6%
Halozyme Therapeutics Inc logo

HALO - Manufacturing

Halozyme Therapeutics Inc

P/E-Ratio
15.6
Total Investment
$122 Million
Weight
1.6%
CRISPR Therapeutics AG logo

CRSP - Manufacturing

CRISPR Therapeutics AG

P/E-Ratio
-18.6
Total Investment
$116 Million
Weight
1.5%
Madrigal Pharmaceuticals Inc logo

MDGL - Manufacturing

Madrigal Pharmaceuticals Inc

P/E-Ratio
-13.5
Total Investment
$109 Million
Weight
1.4%
Avidity Biosciences Inc logo

RNA - Manufacturing

Avidity Biosciences Inc

P/E-Ratio
-16.8
Total Investment
$105 Million
Weight
1.4%
Krystal Biotech Inc logo

KRYS - Manufacturing

Krystal Biotech Inc

P/E-Ratio
101.6
Total Investment
$95.9 Million
Weight
1.2%